Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer | Applied Clinical Trials Online
Imfinzi Regimen Demonstrates Survival Benefit in Early Gastric and GEJ Cancer The Phase III MATTERHORN trial has shown a 22% reduction in the risk of death for patients with early-stage ga…